Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 2/20 | 0.64 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.64 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.64 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.64 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.64 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.64 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.64 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 5/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ATP12A | P54707 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7389878 | 1.00 | ATP1A1 (0.64) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7389882 | 1.00 | ATP1A1 (0.64) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL10638013 | 1.00 | ATP1A1 (0.64) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL1649319 | 1.00 | ATP1A1 (0.64) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL642564 | 0.99 | ATP1A1 (0.63) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Phosphoric Acid SCHEMBL7997964 | 0.95 | ATP1A1 (0.62) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL11566351 | 0.87 | ATP1A1 (0.51) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL11211273 | 0.86 | ATP1A1 (0.53) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Dextrose SCHEMBL11214382 | 0.86 | ATP1A1 (0.53) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL11212478 | 0.86 | ATP1A1 (0.52) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 821 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102542-A1 | ATPASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NON-NEUROLOGICAL DISORDERS | HAPLO THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | WO | claimed |
| WO-2026106785-A1 | 2-OXOGLUTARATE-DEPENDENT DIOXYGENASES AND METHODS OF USE THEREOF | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2025215232-A1 | A COMPOSITION COMPRISING A SAPONIN AND/OR AN ANTHELMINTIC AND/OR A MITOCHONDRIAL UNCOUPLER FOR THE TREATMENT OF LIVER DISEASE | RAINCASTLE BIO. LIMITED (GB) | 2025-10-16 | — | — | WO | claimed |
| US-12306185-B2 | Detection of anti-p53 antibodies | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2025-05-20 | — | — | US | claimed |
| WO-2025093735-A2 | AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES | DRUG TARGET IP B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | claimed |
| EP-4490187-A2 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | Immunedge, Inc. (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2024259191-A2 | METHOD AND COMPOSITIONS FOR TREATING SKIN DISORDERS | PHOENIX BIOTECHNOLOGY, INC. (US) | 2024-12-19 | — | — | WO | claimed |
| US-12134787-B2 | Method for increasing the yield of oxidosqualene, triterpenes and/or triterpenoids and host cell therefore | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2024-11-05 | — | — | US | claimed |
| US-20240272154-A1 | DETECTION OF ANTI-p53 ANTIBODIES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2024-08-15 | — | — | US | claimed |
| US-4331802-A | Organometallic reagents and their use in the synthesis of cardenolides and isocardenolides | ADVANCE BIOFACTURES CORPORATION (US) | 1982-05-25 | — | — | US | claimed |
| EP-0027023-A1 | Furyl intermediates of cardenolides, their synthesis and production of cardenolides and their isomers therefrom | Advance Biofactures Corporation (US) | 1981-04-15 | — | — | EP | claimed |
| US-4259240-A | Synthesis of furyl intermediates, and cardenolides and their isomers prepared therefrom | ADVANCE BIOFACTURES CORPORATION (US) | 1981-03-31 | — | — | US | claimed |
| US-4219549-A | CARDIOTONIC AGENTS | ETABLISSEMENTS NATIVELLE S.A. (FR) | 1980-08-26 | — | — | US | claimed |
| US-4217280-A | Amino-3-cardenolide derivatives, process for their preparation, and pharmaceutical compositions containing same | ETABLISSEMENTS NATIVELLE S.A. (FR) | 1980-08-12 | — | — | US | claimed |
| US-4184037-A | RADIOIMMUNOASSAY | BURROUGHS WELLCOME CO. (US) | 1980-01-15 | — | — | US | claimed |
| US-4175078-A | Cardenolide and bufadienolide derivatives of ajmaline and process for producing same | Kharkovsky Naucho-Issledovatelsky Khimfo-Farmatsevtiches-Ky Institut (SU) | 1979-11-20 | — | — | US | claimed |
| US-4102884-A | TREATING A 3,14-DIHYDROXY-CARDENOLIDE WITH OXYGEN AND N-BROMOACETAMIDE IN THE PRESENCE OF PLATINUM, THEN WITH ETHANEDITHIOL, RANEY NICKEL | STEELE CHEMICALS CO. LTD. (CA) | 1978-07-25 | — | — | US | claimed |
| US-4097477-A | Steroid compounds and processes thereof | STEELE CHEMICALS CO. LTD. (CA) | 1978-06-27 | — | — | US | claimed |
| US-4060607-A | Cardenolide derivatives | ETABLISSEMENTS NATIVELLE S.A. (FR) | 1977-11-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, MPL, PRLHR | ATP1A1 4524/4885ATP1B1 4724/4885ATP1A3 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.